Topic
Hair loss treatment ladder
An evidence-ranked ladder of options for pattern hair loss in men and in women, with doses as studied and links to the studies, plus where to go for other causes of hair loss.
This is an evidence-ranked summary for pattern (androgenetic) hair loss, split by sex, plus short routes for other causes. Options are ranked by how strong the evidence is, from several randomized trials or meta-analyses down to preclinical work, marketing claims only, and options that failed or were harmful. Doses appear only as used in studies. Medicines and procedures here are information, not advice.
First make sure the diagnosis is pattern loss. Sudden shedding, round patches, scalp symptoms, scarring signs or loss in children are not ladder problems; see when to see a dermatologist.
Key takeaways
- The proven core is small: topical minoxidil, oral finasteride for men and dutasteride (off-label in most countries), all backed by several randomized trials and, for women, minoxidil plus selected anti-androgens. A 2026 network meta-analysis of off-label male therapies again ranked topical minoxidil 5% most effective (Gupta 2026).
- Add-ons come second: low-level light, microneedling with minoxidil and PRP. Hair transplant is a surgical rung for stable loss.
- Most natural options have limited evidence at best, and supplements fix only a proven deficiency (see iron and ferritin and zinc). Biotin has no shown benefit for hair loss without a deficiency.
- Women and men differ. Finasteride 1 mg showed no benefit over placebo in the Cochrane review for women (47 trials, 5,290 participants) while minoxidil did (van Zuuren 2016). A network meta-analysis ranked finasteride 5 mg/day top for women, but from sparse data (Gupta 2024). Pregnancy rules out several rungs for women.
- Results take 4 to 6 months and stop when treatment stops. An international panel expects a clinical response to oral minoxidil within 4 to 6 months (Gupta 2026 Delphi).
- Start early. Guidelines exist for both sexes (Kanti 2018), and the female pattern loss expert report starts treatment with minoxidil 5% (Carmina 2019).
The ladder for men (Norwood stage)
| Rung | Option | Dose as studied | Notes |
|---|---|---|---|
| 0 | Baseline: scalp health, stop traction, check iron and thyroid if shedding | n/a | See hair loss scales and DHT and pattern hair loss |
| 1 | Topical minoxidil | 5% solution twice daily in the pivotal trial, 5% foam labelled twice daily for men | 5% grew about 45% more hair than 2% at 48 weeks (Olsen 2002; label) |
| 1 | Oral finasteride | 1 mg/day | Added 107 hairs over placebo at 1 year in a 5.1 cm2 vertex circle (Kaufman 1998); 12-trial meta-analysis in Mella 2010. Prescription only; mood and sexual-effect concerns (see post-finasteride syndrome) |
| 2 | Low-dose oral minoxidil | Common start 2.5 mg/day in men (range 1.25 to 5) (Akiska 2025) | Off-label, prescription; cardiovascular caution |
| 2 | Dutasteride | 0.5 mg/day in most trials | 2.5 mg beat finasteride 5 mg in a 416-man trial (Olsen 2006); 0.5 mg in Gubelin Harcha 2014. Approved for hair only in South Korea and Japan |
| 3 | Low-level laser or light | About 650 to 655 nm, 8 to 25 minutes, 3 times a week or every other day | Gains of 18 to 26 vs 2 to 9 hairs per cm2 at 26 weeks (Jimenez 2014); mostly industry-funded |
| 3 | Microneedling plus minoxidil | 0.6 to 1.5 mm needles, weekly to monthly | Add-on only; the largest trial found no extra benefit (Liu 2026) |
| 3 | PRP | 3 monthly sessions then maintenance | Pooled gain about 27.5 hairs per cm2 with extreme heterogeneity (Kieling 2024) |
| 4 | Hair transplant | Surgery; finasteride 1 mg/day from 4 weeks before to 48 weeks after in the trial | Medical therapy protects native hair: 94% vs 67% visibly better (Leavitt 2005); survival 85 to 93% (Stoneburner 2020) |
| 4 | Hairline lowering | Surgery | Mostly for stable high hairlines in women |
| - | Cosmetics: caffeine, rosemary oil, melatonin, adenosine | See each page | Weaker data; adjunct only. The 2025 Canadian consensus rejected caffeine, rosemary oil and adenosine (Landells 2025) |
| - | Biotin | n/a | No benefit without deficiency |
| - | Exosomes, stem-cell and similar injectables | n/a | Preclinical and early clinical data; not a standard rung (Nareswari 2026) |
By Norwood stage, practically: at stage I to II (early recession or a thin crown), rung 1 is usually enough to hold and may thicken. At stage III to IV, rungs 1 and 2 plus consider rung 3. At stage V to VII, medication slows further loss, but coverage needs a transplant or styling (see haircuts and face shape and hair density). Very advanced loss with a thin donor area may suit a buzz style.
The ladder for women (Ludwig and Savin scales)
| Rung | Option | Dose as studied | Notes |
|---|---|---|---|
| 0 | Look for causes: iron deficiency, thyroid, PCOS or other androgen excess, new medication | n/a | Assess androgen excess in all female pattern loss (Carmina 2019); see PCOS and hair |
| 1 | Topical minoxidil | 2% solution twice daily or 5% foam once daily (US label) | 2% and 5% showed no clear hair-count difference (van Zuuren 2016; Lucky 2004; label) |
| 2 | Low-dose oral minoxidil | Common start 1.25 mg/day in women (range 0.625 to 5) (Akiska 2025) | Avoid in pregnancy; off-label, prescription |
| 2 | Spironolactone | 100 mg/day in a 2025 trial (Werachattawatchai 2025); 25 mg with low-dose oral minoxidil in a series (Sinclair 2018) | Off-label; contraindicated in pregnancy; the 100 mg add-on did not reach statistical significance, and bicalutamide 50 mg was slightly ahead on trichoscopy only (Jha 2026) |
| 3 | 5-alpha-reductase inhibitors (finasteride, dutasteride) | Finasteride 1 mg showed no benefit; trials used 2.5 to 5 mg | Off-label; mixed results; not for pregnancy or potential pregnancy |
| 3 | Low-level laser | As for men | Cochrane found hair-count gains but no clear participant-rated benefit |
| 3 | Microneedling, PRP | As for men | Adjuncts |
| 4 | Transplant | Surgery | Needs a stable pattern and good donor area |
Pregnancy and breastfeeding: minoxidil, finasteride, dutasteride and spironolactone are all to be avoided or specifically discussed with a doctor (Brinks 2026). Pregnant women should not handle crushed finasteride tablets.
Other causes: where to go
| Situation | Route |
|---|---|
| Round patches, sudden | Alopecia areata; see a dermatologist. Baricitinib is approved for severe adult cases (2 or 4 mg once daily in the pivotal trials (King 2022)) |
| Diffuse shedding 2 to 4 months after illness, surgery, birth or diet change | Telogen effluvium or postpartum hair loss; usually self-limiting; check ferritin and thyroid |
| Pain, itch, scale, shiny smooth patches | Scarring alopecias: lichen planopilaris, frontal fibrosing alopecia, CCCA; dermatologist soon |
| Hairline loss from tight styles | Traction alopecia |
| Scaly patch, broken hairs, child | Tinea capitis; needs an oral antifungal |
| Hair pulling | Trichotillomania |
| Hair loss during chemotherapy | Anagen effluvium and scalp cooling |
| Breakage with a normal scalp | Hair shaft disorders |
Hair type notes
- Curl 3A to 4C: pattern loss is under-recognized because volume hides density, and CCCA and traction are more common. Ask a clinician to examine the crown and hairline.
- Fine, low-density hair shows loss earliest, so take baseline photos (see hair in photos).
- An oily or flaky scalp should be treated first, because inflammation can mimic or worsen thinning.
- On a budget, minoxidil plus generic finasteride is the cheapest evidence-based pairing for men; for women, minoxidil plus (if suitable) spironolactone.
Myths and facts
- Shampoos do not regrow hair. Cleansing does not treat pattern loss.
- Not everything works equally. The gap between strong evidence and lab-only evidence is large.
- Combinations such as minoxidil with a 5-alpha-reductase inhibitor are common in practice.
Bottom line
Photograph the scalp in the same light before starting, and reassess at 6 and 12 months. Choose rung 1 first unless a clinician advises otherwise, and do not stack unproven products before proven ones. Stop and seek review for chest pain, swelling or dizziness with oral minoxidil, and for mood or sexual changes with finasteride. If you could become pregnant, check your plans before any prescription step. Discuss with a doctor.
Studies 27
Gupta AK et al. Beyond minoxidil: off-label therapies for male androgenetic alopecia - network meta-analyses. Medicina. 2026
Tested: off-label therapies compared in network meta-analyses
Result: Topical minoxidil 5% was again ranked most effective.
Read the study ↗van Zuuren EJ et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016
Tested: topical minoxidil and other treatments vs placebo
Result: Minoxidil gave about 13.2 more hairs/cm2 than placebo; there was no difference between 2% and 5% in women.
Read the study ↗Gupta AK et al. 5-alpha-reductase inhibitors and minoxidil monotherapy for female pattern hair loss: network meta-analysis. J Cosmet Dermatol. 2024
Tested: finasteride 5 mg/day, topical minoxidil 5% twice daily, oral minoxidil 1 mg/day
Result: Finasteride 5 mg/day for 24 weeks ranked top on hair density, then topical minoxidil 5%, then oral minoxidil 1 mg/day; data were sparse.
Read the study ↗Kanti V et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2018
Result: A European guideline states pattern hair loss affects up to 80% of white men and 42% of women over a lifetime.
Read the study ↗Carmina E et al. Female pattern hair loss and androgen excess: a report from the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019
Tested: expert report
Result: Every woman with female pattern loss should be assessed for androgen excess; isolated loss with normal androgens is not a sign of hyperandrogenism; start treatment with minoxidil 5%.
Read the study ↗Akiska YM et al. Low-dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement. JAMA Dermatol. 2025
Tested: low-dose oral minoxidil practice
Result: Common starting doses were 1.25 mg/day in adult women and 2.5 mg/day in adult men; pregnancy, past pericardial effusion and heart failure were contraindications.
Read the study ↗Show 21 more studies
Gupta AK et al. Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern hair loss in hair transplant patients using a modified Delphi process. Expert Opin Pharmacother. 2026
Tested: oral and topical minoxidil around transplant surgery
Result: Consensus covers restarting low-dose oral minoxidil 1-3 days after surgery and topical minoxidil on grafts at 7-14 days; start doses of 1.25-2.5 mg/day in men and 0.625-1.25 mg/day in women.
Read the study ↗Brinks AL et al. Safety of alopecia therapies during pregnancy, fertility treatment and PCOS workup. Int J Womens Dermatol. 2026
Tested: alopecia therapies
Result: Anti-androgens and 5-alpha-reductase inhibitors are unsuitable in pregnancy; some therapies can alter hormone labs or mask PCOS signs.
Read the study ↗Olsen EA et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002
Tested: 5% vs 2% topical minoxidil solution vs placebo, twice daily
Result: 5% was superior to 2% and placebo, with about 45% more regrowth than 2% at week 48 and faster onset; itch and irritation were more common with 5%.
Read the study ↗Lucky AW et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004
Tested: 5% vs 2% topical minoxidil vs placebo, twice daily
Result: Both strengths beat placebo on hair counts; 5% was better than 2% only on patient-rated benefit and caused more itch and facial hair.
Read the study ↗Minoxidil 5% topical foam for women, over-the-counter drug facts. DailyMed
Tested: 5% minoxidil foam, half a capful once daily
Result: Results may appear at 3 months and some women need at least 6 months; hair loss begins again if use stops; the foam is extremely flammable and may be harmful in pregnancy or breastfeeding.
Read the study ↗Minoxidil 5% topical foam for men, over-the-counter drug facts. DailyMed
Tested: 5% minoxidil foam, half a capful twice daily
Result: Labelled for regrowth on the top of the scalp (vertex) only, not for a receding hairline; using more or more often will not improve results.
Read the study ↗Kaufman KD et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998
Tested: finasteride 1 mg/day vs placebo
Result: Finasteride grew about 107 more hairs than placebo at 1 year and about 138 more at 2 years in a 5.1 cm2 vertex circle (baseline about 876); placebo men kept losing hair.
Read the study ↗Mella JM et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010
Tested: finasteride vs placebo
Result: Number needed to treat was 5.6 (up to 12 months) and 3.4 (24 months or more) for self-perceived improvement; erectile dysfunction relative risk 2.22 (about 1 extra case per 82 men).
Read the study ↗Olsen EA et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006
Tested: dutasteride 0.05-2.5 mg vs finasteride 5 mg vs placebo
Result: Hair gain rose with dutasteride dose; 2.5 mg beat finasteride at 12 and 24 weeks. GSK-funded.
Read the study ↗Gubelin Harcha W et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014
Tested: dutasteride 0.02, 0.1 or 0.5 mg vs finasteride 1 mg vs placebo
Result: Dutasteride 0.5 mg beat finasteride 1 mg on hair count, hair width and frontal photos; adverse events were similar. GSK-funded.
Read the study ↗Werachattawatchai P et al. Oral spironolactone for female pattern hair loss in premenopausal women: placebo-controlled pilot randomized controlled trial. Int J Womens Dermatol. 2025
Tested: spironolactone 100 mg vs placebo
Result: Moderate-to-marked improvement in 38% vs 9% (p = 0.034); terminal hairs +9.5 vs +5.3/cm2 (p = 0.063); menstrual irregularity 37.5%.
Read the study ↗Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018
Tested: oral minoxidil 0.25 mg plus spironolactone 25 mg daily
Result: Severity score fell 1.3 points and shedding score fell 2.6; no hyperkalaemia.
Read the study ↗Jha AK et al. Spironolactone vs bicalutamide in female pattern hair loss: randomized clinical trial. Clin Exp Dermatol. 2026
Tested: bicalutamide 50 mg vs spironolactone 100 mg
Result: Frontal hair count rose 5.05 vs 3.13/cm2 favouring bicalutamide (p<0.001); vertex 6.32 vs 3.06; the authors found no significant difference in clinical endpoints; adverse events 11.7% vs 18.6%.
Read the study ↗Jimenez JJ et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014
Tested: HairMax laser comb 3 times a week vs sham
Result: Terminal hair gains of 18-26 per cm2 vs 2-9 with sham. Partly maker-funded.
Read the study ↗Liu Y et al. Microneedle frequency adjunct to 2% minoxidil in female androgenetic alopecia: a randomized controlled trial. J Am Acad Dermatol. 2026
Tested: 2% minoxidil alone or with 0.5-0.55 mm microneedling every 2 or 4 weeks
Result: All three groups improved by the same amount; microneedling added no benefit. Open-label.
Read the study ↗Kieling L et al. Is autologous platelet-rich plasma capable of increasing hair density in patients with androgenic alopecia? A systematic review and meta-analysis of randomized clinical trials. An Bras Dermatol. 2024
Tested: PRP vs placebo
Result: About +27.5 hairs per cm2 vs placebo, no significant change in diameter; I2 96% and publication bias, so low quality.
Read the study ↗Stoneburner J et al. Contemporary management of alopecia: a systematic review and meta-analysis for surgeons. Aesthetic Plast Surg. 2020
Tested: hair transplantation
Result: Pooled graft survival about 85% with micrografts and 93% with micro- plus minigrafts; satisfaction 90-97% in non-scarring alopecia.
Read the study ↗Leavitt M et al. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg. 2005
Tested: finasteride 1 mg/day vs placebo
Result: Visible frontal improvement in 94% on finasteride vs 67% on placebo.
Read the study ↗Nareswari A et al. Exosome-based therapy for androgenetic alopecia: a systematic review of preclinical mechanisms and efficacy. Acta Dermatovenerol Alp Pannonica Adriat. 2026
Tested: exosome therapy
Result: Better coverage, follicle size and growth-phase ratio in mostly mouse models.
Read the study ↗King B et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022
Tested: baricitinib 2 mg or 4 mg daily vs placebo
Result: At least 80% scalp hair at week 36: 38.8% (4 mg), 22.8% (2 mg), 6.2% (placebo) in trial 1; 35.9%, 19.4%, 3.3% in trial 2.
Read the study ↗Landells I et al. A Canadian consensus on androgenetic alopecia. J Cutan Med Surg. 2025
Tested: expert ratings of 17+ interventions
Result: Recommended oral and topical finasteride, oral dutasteride, minoxidil, PRP and microneedling; listed flutamide among interventions not recommended.
Read the study ↗Related
- MinoxidilThe most widely used hair-growth treatment, available as a cheap over-the-counter lotion or foam and as a prescription tablet, with a mechanism that is still only partly understood.
- FinasterideA prescription pill (and in some countries a scalp spray) that lowers DHT and is the best-proven drug for stopping male pattern hair loss.
- DutasterideA stronger cousin of finasteride that blocks both forms of the DHT-making enzyme and grew more hair than finasteride in head-to-head trials.
- SpironolactoneA cheap blood-pressure pill that blocks androgen receptors and is the most widely used off-label hormonal treatment for women's pattern hair loss.
- BaricitinibA once-daily pill that was the first drug approved for severe alopecia areata, regrowing hair in about a third of patients while they keep taking it.
- BiotinA B vitamin that restores hair only in the rare people who are deficient, and that can scramble thyroid and heart blood tests at the doses sold for hair.
- Iron and ferritinLow iron stores are common in people who shed hair, but no trial has shown that iron pills regrow hair, and nobody agrees on a hair-specific ferritin target.
- ZincTrue zinc deficiency causes hair loss that zinc fixes, but zinc has not been shown to regrow hair in people who are not deficient, and too much causes copper deficiency.
- Caffeine (topical)Caffeine in shampoos and leave-on liquids clearly stimulates hair follicles in the lab, but the human trials are small, mostly industry-run and mostly on blends.
- Rosemary oilRosemary oil became the internet's "natural minoxidil" from one small 2015 trial that had no placebo group and has never been replicated.
- Melatonin (topical)Hair follicles make their own melatonin, and a small 2004 trial found a scalp solution raised the share of growing hairs in women, but later studies are uncontrolled and sponsored by the maker.
- Adenosine (topical)Adenosine, a natural signalling molecule, is the cosmetic hair active with the cleanest small placebo-controlled trials, mainly making thin hairs thicker.
- Low-level laser therapy (red-light caps, combs and helmets)Red-light lasers and LEDs worn as caps, combs or helmets add a modest amount of hair over sham devices in mostly industry-funded trials.
- Microneedling for hair lossRolling or stamping fine needles into the scalp is a cheap add-on to minoxidil that helped in small trials, but it has not worked on its own and the largest trial found no extra benefit.
- Platelet-rich plasma (PRP) for hair lossYour own blood is spun to concentrate platelets and injected into the scalp; pooled trials show a modest gain, but individual trials conflict and each session is costly.
- Hair transplant (FUE, FUT, DHI, beard and brow)A transplant moves balding-resistant follicles from the back and sides of the scalp, or the beard, into thinning areas; most grafts survive, but donor hair is finite and cheap clinics cause real harm.
- Hairline-lowering (forehead-reduction) surgerySurgeons remove a strip of forehead skin at the hairline and pull the scalp forward to lower a naturally high hairline in one operation, mostly for women with a stable hairline.
- Exosomes (extracellular vesicles) for hair lossExosomes are tiny packets released by lab-grown cells that clinics inject or apply to the scalp; animal data look good, human data are small and mostly uncontrolled, and no exosome product is approved in the US.
- Stem cell and growth factor treatments for hair lossClinics inject fat-derived cells, the fluid those cells grew in, or concentrated growth factors into the scalp; small trials mostly report gains, the best-controlled show little advantage, and none of it is approved for hair.
- Androgenetic alopecia (male and female pattern hair loss)The most common cause of hair loss is an inherited, slowly progressive shrinking of scalp follicles; it cannot be cured, but finasteride, minoxidil and transplants slow, partly reverse or camouflage it.
- PCOS and hairPolycystic ovary syndrome can cause female-pattern scalp thinning plus unwanted facial and body hair from excess androgens, but pattern hair loss alone does not prove PCOS.
- Alopecia areataAn autoimmune condition where the immune system attacks growing hair follicles, causing round patches or total hair loss; three oral JAK inhibitors are approved for severe cases but hair usually goes again when treatment stops.
- Lichen planopilarisAn immune-mediated scarring hair loss, mainly on the crown and sides, that destroys follicles permanently; early treatment aims to stop activity because lost hair does not return.
- Frontal fibrosing alopeciaA scarring hair loss that pulls the front and temple hairline back, often with eyebrow thinning; lost follicles do not return, so treatment aims to stop progression early.
- Central centrifugal cicatricial alopecia (CCCA)The most common scarring hair loss in women of African descent, starting at the crown and spreading outward; early diagnosis matters because lost follicles are replaced by scar.
- Traction alopeciaHair loss from repeated or constant pulling on the follicle by tight braids, weaves, buns or ponytails; it starts reversible but can become permanent if the tension continues.
- Tinea capitis (scalp ringworm)A fungal infection of scalp skin and hair shafts that mostly affects children but also adults; it needs oral antifungal medicine, and shampoo alone will not cure it.
- Trichotillomania (hair-pulling disorder)A recognized disorder of repeatedly pulling out your own hair despite trying to stop; behavioural therapy such as habit reversal training is the best-supported treatment.
- Hair shaft disordersStructural defects in the hair strand itself, either inherited or caused by repeated stress, that make hair break easily and can look like thinning even though the follicle is healthy.
- When to see a dermatologistMost gradual thinning is pattern loss you can start treating yourself, but scarring signs, scalp symptoms, patches or sudden shedding should go to a clinician quickly because delay can cost permanent hair.
- Hair loss scales, hairlines and how to classify your own hair lossThe Norwood, Ludwig, Sinclair and BASP scales describe pattern hair loss in broad bands, and this page explains how reliable they are, how well people can stage themselves and how to tell a mature hairline from a receding one.
- DHT and pattern hair lossPattern hair loss happens when genetically sensitive scalp follicles respond to the hormone DHT by shrinking a little more with every hair cycle.
- Post-finasteride syndromeSome men report sexual, mental and physical symptoms that start on finasteride and last after stopping; whether it is a distinct drug-caused condition is still unresolved.
- The hair growth cycleEvery scalp follicle cycles through growth, shutdown, rest and release on its own clock, which explains normal shedding, seasonal changes, maximum length and how pattern hair loss works.